BioTime, USCN sign option, distribution agreements
February 2012

ALAMEDA, Calif.óBioTime Inc. has announced agreements with USCN Life Science Inc. (USCN) that grant BioTime an option to license USCN's antibody-producing cell lines and certain related technology that BioTime and its subsidiary OncoCyte Corp. can use for the large-scale manufacture of the antibody components of PanC-Dx. A novel diagnostic technology, PanC-Dx was discovered at BioTime and OncoCyte and is intended to detect the presence of various cancers, including breast, colon, lung, stomach, uterine and bladder cancers. BioTime and USCN also signed a distribution agreement that grants BioTime and its subsidiaries the right to market more than 4,000 diverse ELISA and CLIA kits for detecting a wide array of proteins for the stem cell research market, which BioTime intends to sell through its subsidiary LifeMap Sciences Inc. in 2012.  

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.